Shares of little-known Corbus Pharmaceuticals (NASDAQ:CRBP) are absolutely skyrocketing today. At the time of writing, CRBP stock is up more than 300%, as investors price in a key announcement from the company. Earlier today, Corbus announced that its next-generation antibody drug (CRB-701) showed strong safety and efficacy in a first-in-human study on its effects on cervical cancer tumors. This drug conjugate is one of three key drugs that are currently in clinical trial phases but has clearly moved up the ...